[Pharmacokinetics of haloperidol in patients on hemodialysis]. 1998

M Sanga, and J Shigemura
Department of Psychiatry, Tachikawa Hospital, Tokyo, Japan.

Psychotic symptoms among patients receiving hemolytic dialysis (HD) are quite common, while studies showing pharmacokinetics and clearances of neuroleptics in such patients are few. In such instances, previous studies recommended a single administration of neuroleptics with about 1/3 to 1/2 of the normal dose for patients without renal failure. We made a study of 4 cases of delirious patients receiving HD and investigated the relationship between a daily dose of haloperidol (HP), its blood concentration and changes of delirium symptoms before and after HD. Oral or intravenous doses of HP (12-24 mg) were required for the improvement of delirium. Blood concentration increased in proportion to the HP dosage in all patients, and its average was significantly higher than that of the control group. Approximately 25% of clearance was found before and after HD. These studies suggest that the HP dosage for HD patients needs to be larger than previously assumed. Changes in the pharmacokinetics of HP in HD patients seemed to be influenced by a variety of factors such as binding rate with blood serum albumin and HP, metabolic pathway of HP, and sensitivity of HP in the brain.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

M Sanga, and J Shigemura
January 1987, Psychopharmacology,
M Sanga, and J Shigemura
January 1988, Acta medica Iugoslavica,
M Sanga, and J Shigemura
December 1989, Clinical pharmacokinetics,
M Sanga, and J Shigemura
January 1997, European journal of clinical pharmacology,
M Sanga, and J Shigemura
May 2001, International journal of clinical pharmacology and therapeutics,
M Sanga, and J Shigemura
January 1991, Infection,
M Sanga, and J Shigemura
January 1991, Renal failure,
Copied contents to your clipboard!